The p53R172H Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression
Authors:
Open Access
- 17 April 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (4) , e0123816
Abstract
Hepatocellular carcinoma is a highly deadly malignancy, accounting for approximately 800,000 deaths worldwide every year. Mutation of the p53 tumor suppressor gene is a common genetic change in HCC, present in 30% of cases. p53R175H (corresponding to p53R172H in mice) is a hotspot for mutation that demonstrates “prometastatic” gain-of-function in other cancer models. Since the frequency of p53 mutation increases with tumor grade in HCC, we hypothesized that p53R172H is a gain-of-function mutation in HCC that contributes to a decrease in tumor-free survival and an increase in metastasis. In an HCC mouse model, we found that p53R172H/flox mice do not have decreased survival, increased tumor incidence, or increased metastasis, relative to p53flox/flox littermates. Analysis of cell lines derived from both genotypes indicated that there are no differences in anchorage-independent growth and cell migration. However, shRNA-mediated knockdown of mutant p53 in p53R172H-expressing HCC cell lines resulted in decreased cell migration and anchorage-independent growth. Thus, although p53 mutant-expressing cells and tumors do not have enhanced properties relative to their p53 null counterparts, p53R172H-expressing HCC cells depend on this mutant for their transformation. p53 mutants have been previously shown to bind and inhibit the p53 family proteins p63 and p73. Interestingly, we find that the levels of p63 and p73 target genes are similar in p53 mutant and p53 null HCC cells. These data suggest that pathways regulated by these p53 family members are similarly impacted by p53R172H in mutant expressing cells, and by alternate mechanisms in p53 null cells, resulting in equivalent phenotypes. Consistent with this, we find that p53 null HCC cell lines display lower levels of the TA isoforms of p63 and p73 and higher levels of ΔNp63. Taken together these data point to the importance of p63 and p73 in constraining HCC progression.Keywords
This publication has 41 references indexed in Scilit:
- The gain of function of p53 cancer mutant in promoting mammary tumorigenesisOncogene, 2012
- Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patientsWorld Journal of Gastroenterology, 2012
- Association of TP53 Mutations With Stem Cell-Like Gene Expression and Survival of Patients With Hepatocellular CarcinomaGastroenterology, 2011
- Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinomaBiochemical and Biophysical Research Communications, 2010
- Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancerProceedings of the National Academy of Sciences, 2010
- Mutant p53 Gain-of-Function in CancerCold Spring Harbor Perspectives in Biology, 2009
- p63 and p73 Transcriptionally Regulate Genes Involved in DNA RepairPLOS Genetics, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Loss of p53 and Ink4a/Arf Cooperate in a Cell Autonomous Fashion to Induce Metastasis of Hepatocellular Carcinoma CellsCancer Research, 2007
- p73 Is up-regulated in a subset of hepatocellular carcinomasHepatology, 2000